BRUSSELS (Reuters) – Eli Lilly plus Co can keep its dividend inspite of the erosion of its earnings by generic duplicates of blockbuster drugs plus ought to be perfectly located by the finish of 2013 to assess the potential of its future drugs, its chief executive mentioned. The U.S. drugmaker suffered a 7 % drop inside revenue last year along with a 6 % decline inside web profit following it lost U.S. patent security of top-selling schizophrenia drug Zyprexa. Conversely, the business which brought Prozac to the globe has 13 drug individuals inside stage III trials, the many inside its history. Major U.S. …
There are no comments yet. Why not be the first to speak your mind.